JPWO2019211665A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019211665A5 JPWO2019211665A5 JP2020558493A JP2020558493A JPWO2019211665A5 JP WO2019211665 A5 JPWO2019211665 A5 JP WO2019211665A5 JP 2020558493 A JP2020558493 A JP 2020558493A JP 2020558493 A JP2020558493 A JP 2020558493A JP WO2019211665 A5 JPWO2019211665 A5 JP WO2019211665A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- isolated antibody
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 65
- 239000000427 antigen Substances 0.000 claims 62
- 102000036639 antigens Human genes 0.000 claims 62
- 108091007433 antigens Proteins 0.000 claims 62
- 238000006467 substitution reaction Methods 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 229930003827 cannabinoid Natural products 0.000 claims 5
- 239000003557 cannabinoid Substances 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims 3
- 229960003015 rimonabant Drugs 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000008484 agonism Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000005932 Alstrom Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 claims 1
- 101000703681 Homo sapiens Single-minded homolog 1 Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 102100031980 Single-minded homolog 1 Human genes 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024014317A JP2024059646A (ja) | 2018-04-30 | 2024-02-01 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664882P | 2018-04-30 | 2018-04-30 | |
| US62/664,882 | 2018-04-30 | ||
| PCT/IB2019/000503 WO2019211665A1 (en) | 2018-04-30 | 2019-04-29 | Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014317A Division JP2024059646A (ja) | 2018-04-30 | 2024-02-01 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525059A JP2021525059A (ja) | 2021-09-24 |
| JPWO2019211665A5 true JPWO2019211665A5 (enExample) | 2022-05-11 |
| JP7431750B2 JP7431750B2 (ja) | 2024-02-15 |
Family
ID=67396963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558493A Active JP7431750B2 (ja) | 2018-04-30 | 2019-04-29 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
| JP2024014317A Pending JP2024059646A (ja) | 2018-04-30 | 2024-02-01 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014317A Pending JP2024059646A (ja) | 2018-04-30 | 2024-02-01 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US12202901B2 (enExample) |
| EP (1) | EP3787746A1 (enExample) |
| JP (2) | JP7431750B2 (enExample) |
| KR (1) | KR20210005051A (enExample) |
| CN (1) | CN112218684A (enExample) |
| AR (1) | AR114436A1 (enExample) |
| AU (1) | AU2019264029A1 (enExample) |
| BR (1) | BR112020022035A2 (enExample) |
| CA (1) | CA3098416A1 (enExample) |
| CL (1) | CL2020002793A1 (enExample) |
| CO (1) | CO2020014681A2 (enExample) |
| EA (1) | EA202092593A1 (enExample) |
| EC (1) | ECSP20076576A (enExample) |
| MA (1) | MA52504A (enExample) |
| MX (1) | MX2020011498A (enExample) |
| PE (1) | PE20210419A1 (enExample) |
| PH (1) | PH12020551805A1 (enExample) |
| SG (1) | SG11202010388SA (enExample) |
| TW (1) | TWI882957B (enExample) |
| WO (1) | WO2019211665A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020011498A (es) * | 2018-04-30 | 2021-01-29 | Takeda Pharmaceuticals Co | Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas. |
| WO2023234406A1 (ja) | 2022-06-03 | 2023-12-07 | 塩野義製薬株式会社 | カンナビノイド１型受容体に結合する抗体 |
| WO2023242843A1 (en) * | 2022-06-17 | 2023-12-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Peripheralization of centrally-acting cannabinoid-1 receptor antagonists by nanoparticles for the treatment metabolic related conditions |
| CN119585311A (zh) * | 2022-07-28 | 2025-03-07 | 长春金赛药业有限责任公司 | 结合大麻素受体cb1的抗体及其用途 |
| WO2025257151A1 (en) * | 2024-06-10 | 2025-12-18 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for treating ciliopathies |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
| US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
| US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
| CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
| US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
| WO2005023232A2 (en) | 2003-09-04 | 2005-03-17 | Affibody Ab | Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
| US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
| US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| BRPI0913406A2 (pt) | 2008-06-03 | 2018-01-09 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
| JP6562912B2 (ja) * | 2013-06-26 | 2019-08-21 | アムジェン インコーポレイテッド | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| CA2944049A1 (en) * | 2014-03-27 | 2015-10-01 | Bird Rock Bio, Inc. | Antibodies that bind human cannabinoid 1 (cb1) receptor |
| US10277406B1 (en) * | 2014-09-05 | 2019-04-30 | Digicert, Inc. | Authentication process for issuing sequence of short-lived digital certificates |
| US10034865B2 (en) | 2015-09-10 | 2018-07-31 | Kashiv Pharma, Llc | Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof |
| EP3356833A4 (en) * | 2015-09-30 | 2019-04-10 | Bird Rock Bio, Inc. | ANTIBODIES FOR BINDING HUMAN CANNABINOID RECEPTOR 1 (CB1) |
| US20210283217A1 (en) | 2016-07-26 | 2021-09-16 | Flagship Pioneering Innovations V, Inc. | Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases |
| MX2020011498A (es) | 2018-04-30 | 2021-01-29 | Takeda Pharmaceuticals Co | Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas. |
-
2019
- 2019-04-29 MX MX2020011498A patent/MX2020011498A/es unknown
- 2019-04-29 AR ARP190101123A patent/AR114436A1/es unknown
- 2019-04-29 SG SG11202010388SA patent/SG11202010388SA/en unknown
- 2019-04-29 EA EA202092593A patent/EA202092593A1/ru unknown
- 2019-04-29 PE PE2020001750A patent/PE20210419A1/es unknown
- 2019-04-29 US US17/052,048 patent/US12202901B2/en active Active
- 2019-04-29 KR KR1020207032056A patent/KR20210005051A/ko not_active Ceased
- 2019-04-29 CN CN201980029451.9A patent/CN112218684A/zh active Pending
- 2019-04-29 MA MA052504A patent/MA52504A/fr unknown
- 2019-04-29 AU AU2019264029A patent/AU2019264029A1/en active Pending
- 2019-04-29 BR BR112020022035-3A patent/BR112020022035A2/pt unknown
- 2019-04-29 EP EP19742647.1A patent/EP3787746A1/en active Pending
- 2019-04-29 JP JP2020558493A patent/JP7431750B2/ja active Active
- 2019-04-29 CA CA3098416A patent/CA3098416A1/en active Pending
- 2019-04-29 WO PCT/IB2019/000503 patent/WO2019211665A1/en not_active Ceased
- 2019-04-30 TW TW108115125A patent/TWI882957B/zh active
-
2020
- 2020-10-27 CL CL2020002793A patent/CL2020002793A1/es unknown
- 2020-10-29 PH PH12020551805A patent/PH12020551805A1/en unknown
- 2020-11-26 CO CONC2020/0014681A patent/CO2020014681A2/es unknown
- 2020-11-27 EC ECSENADI202076576A patent/ECSP20076576A/es unknown
-
2021
- 2021-03-16 US US17/203,291 patent/US11746155B2/en active Active
-
2024
- 2024-02-01 JP JP2024014317A patent/JP2024059646A/ja active Pending
-
2025
- 2025-01-14 US US19/019,913 patent/US20250250341A1/en active Pending